Hyperuricemia and cardiovascular disease risk - PubMed

Affiliations

• PMID: 25192804
• DOI: 10.1586/14779072.2014.957675

Review

Hyperuricemia and cardiovascular disease risk

Claudio Borghi et al. Expert Rev Cardiovasc Ther. 2014 Oct.

Abstract

Uric acid (UA) is the final end product of purine catabolism and is formed from xanthines and hypoxanthines. Hyperuricemia can be secondary to either an exaggerated production of UA that follows high cellular turnover conditions or, most frequently, to a low renal excretion in patients with impaired renal function. Recent data suggest that serum UA (SUA) at high-normal level is associated with cardiovascular disease risk factors and cardiovascular disease, often being a predictor of incident events. Preliminary data suggest that the reduction of SUA level in subjects with normal-high SUA could prevent at least a part of target-organ damage related to high SUA, especially when xanthine oxidase is selectively inhibited.

Keywords: allopurinol; cardiovascular disease risk; epidemiology; febuxostat; pathophysiology; serum uric acid; xanthine-oxidase inhibitors.

Comment in

• Hyperuricemia as a risk factor for cardiovascular disease.

  Katsiki N, Doumas M, Athyros VG, Karagiannis A. Katsiki N, et al. Expert Rev Cardiovasc Ther. 2015 Jan;13(1):19-20. doi: 10.1586/14779072.2015.987129. Epub 2014 Nov 27. Expert Rev Cardiovasc Ther. 2015. PMID: 25428565 No abstract available.

• In response: hyperuricemia as a risk factor for cardiovascular disease.

  Borghi C, Cicero AF. Borghi C, et al. Expert Rev Cardiovasc Ther. 2015 Jan;13(1):21-2. doi: 10.1586/14779072.2015.987130. Epub 2014 Dec 5. Expert Rev Cardiovasc Ther. 2015. PMID: 25479366 No abstract available.

Similar articles

• Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.

  Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C, Anker SD, Doehner W. Ogino K, et al. Circ Heart Fail. 2010 Jan;3(1):73-81. doi: 10.1161/CIRCHEARTFAILURE.109.868604. Epub 2009 Nov 20. Circ Heart Fail. 2010. PMID: 19933411 Clinical Trial.

• An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.

  Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y. Kamatani N, et al. J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S13-8. doi: 10.1097/RHU.0b013e31821d36cc. J Clin Rheumatol. 2011. PMID: 21654265 Clinical Trial.

• The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.

  Nakatsu Y, Seno Y, Kushiyama A, Sakoda H, Fujishiro M, Katasako A, Mori K, Matsunaga Y, Fukushima T, Kanaoka R, Yamamotoya T, Kamata H, Asano T. Nakatsu Y, et al. Am J Physiol Gastrointest Liver Physiol. 2015 Jul 1;309(1):G42-51. doi: 10.1152/ajpgi.00443.2014. Epub 2015 May 21. Am J Physiol Gastrointest Liver Physiol. 2015. PMID: 25999428

• Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition.

  Harzand A, Tamariz L, Hare JM. Harzand A, et al. Congest Heart Fail. 2012 May-Jun;18(3):179-82. doi: 10.1111/j.1751-7133.2011.00262.x. Epub 2011 Nov 9. Congest Heart Fail. 2012. PMID: 22587748 Review.

• Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.

  Ernst ME, Fravel MA. Ernst ME, et al. Clin Ther. 2009 Nov;31(11):2503-18. doi: 10.1016/j.clinthera.2009.11.033. Clin Ther. 2009. PMID: 20109996 Review.

Cited by

• Maternal Cardiovascular Risk Assessment 3-to-11 Years Postpartum in Relation to Previous Occurrence of Pregnancy-Related Complications.

  Hromadnikova I, Kotlabova K, Dvorakova L, Krofta L. Hromadnikova I, et al. J Clin Med. 2019 Apr 20;8(4):544. doi: 10.3390/jcm8040544. J Clin Med. 2019. PMID: 31010048 Free PMC article.

• Relationship between serum uric acid and electrocardiographic alterations in a large sample of general population: data from the Brisighella Heart Study.

  Cicero AF, Rosticci M, Reggi A, Derosa G, Parini A, Grandi E, D'Addato S, Borghi C. Cicero AF, et al. High Blood Press Cardiovasc Prev. 2015 Jun;22(2):129-34. doi: 10.1007/s40292-014-0077-9. Epub 2014 Dec 16. High Blood Press Cardiovasc Prev. 2015. PMID: 25512187

• Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.

  Mitri G, Wittbrodt ET, Turpin RS, Tidwell BA, Schulman KL. Mitri G, et al. J Manag Care Spec Pharm. 2016 Apr;22(4):326-36. doi: 10.18553/jmcp.2016.22.4.326. J Manag Care Spec Pharm. 2016. PMID: 27023686 Free PMC article.

• Hyperuricemia and its related diseases: mechanisms and advances in therapy.

  Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, Pang Y, Zhang C, Zhong Z, Gao J. Du L, et al. Signal Transduct Target Ther. 2024 Aug 28;9(1):212. doi: 10.1038/s41392-024-01916-y. Signal Transduct Target Ther. 2024. PMID: 39191722 Free PMC article. Review.

• Association between Serum Uric Acid Levels and Bone Mineral Density in Postmenopausal Women: A Cross-Sectional and Longitudinal Study.

  Kang S, Kwon D, Lee J, Chung YJ, Kim MR, Namkung J, Jeung IC. Kang S, et al. Healthcare (Basel). 2021 Dec 4;9(12):1681. doi: 10.3390/healthcare9121681. Healthcare (Basel). 2021. PMID: 34946407 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • scite Smart Citations